Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2026-02-25 @ 7:22 PM
Study NCT ID:
NCT00864994
Status:
UNKNOWN
Last Update Posted:
2010-03-29
First Post:
2009-03-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D029424', 'term': 'Pulmonary Disease, Chronic Obstructive'}, {'id': 'D007249', 'term': 'Inflammation'}, {'id': 'D012907', 'term': 'Smoking'}], 'ancestors': [{'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D001519', 'term': 'Behavior'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood will be retained to investigate differences in candidate genes (SNPs) for COPD and CVD between the different groups.'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 60}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2010-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-09', 'completionDateStruct': {'date': '2015-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-03-26', 'studyFirstSubmitDate': '2009-03-18', 'studyFirstSubmitQcDate': '2009-03-18', 'lastUpdatePostDateStruct': {'date': '2010-03-29', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2009-03-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-04', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Smoking history and behaviour, diet and physical activity level assessed by questionnaire'}, {'measure': 'Extensive lung function and CT scanning of the lung, ECG'}, {'measure': 'Candidate genes for muscle dysfunction and CVD risk'}, {'measure': 'Body composition'}, {'measure': 'Systemic inflammation'}, {'measure': 'Advanced Glycosylated Endproduct (AGE)'}, {'measure': 'Glucose Tolerance Test'}, {'measure': 'Risk factors of metabolic syndrome'}, {'measure': '6 minutes walking distance'}, {'measure': 'Handgrip strength'}, {'measure': 'Skeletal muscle function by isokinetic dynamometry'}, {'measure': 'Physical activity level and pattern by accelerometry'}, {'measure': 'Muscle oxidative phenotype, fibre cross-sectional area and molecular signatures obtained in vastus lateralis muscle biopsies before and after incremental cycle ergometry'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['COPD', 'Inflammation', 'Smoking', 'Multiorgan pathology', 'Extra pulmonary manifestations'], 'conditions': ['Chronic Obstructive Pulmonary Disease']}, 'descriptionModule': {'briefSummary': 'There is increasing evidence in the literature that COPD should not be considered as a localised pulmonary disorder but as a systemic disease involving pathology in several extra pulmonary tissues. Well characterized systemic features are a chronic low grade systemic inflammation, altered body composition and a skeletal muscle fibre type shift. There are indications that an absolute or relative increase of fat mass puts COPD patients at increased risk for cardiovascular pathology while muscle atrophy is associated with a high prevalence of osteoporosis and with impaired physical function. The origin of systemic inflammation is poorly understood. Both endogenous and exogenous risk factors contribute to systemic inflammation and extra-pulmonary manifestations of COPD.\n\nOverall objective of study 3:\n\nTo compare the pattern and severity of the systemic inflammatory profile in relation to skeletal muscle weakness and cardiovascular risk profile in COPD patients with mild to moderate disease compared to non-susceptible smokers.\n\nSpecific objectives:\n\n1. To study the relative contribution of pulmonary and extra pulmonary factors on exercise capacity, skeletal muscle function and health status\n2. To relate diet, physical activity and cardiovascular risk factors to body composition, skeletal muscle function and exercise capacity status\n3. To study the influence of the emphysema phenotype on extra pulmonary pathology in COPD\n4. To study muscle fibre type size and composition and to relate muscle oxidative phenotype with insulin sensitivity, inflammation (local and systemic) and molecular signatures of oxidative energy and protein metabolism.\n\nStudy design:\n\nCross-sectional study. Healthy smoking subjects and COPD patients will undergo extensive clinical, metabolic and inflammatory assessment at the university clinics in Groningen, Maastricht and CIRO Horn.\n\nStudy population:\n\nTotally 60 subjects will be included\n\n* 30 healthy subjects who after 20 pack years smoking have no signs of COPD (age 40-75 years)\n* 30 COPD patients with GOLD stage II (age 40-75 years)', 'detailedDescription': 'Primary study parameters/outcome of the study:\n\n1. Smoking history and behaviour, diet and physical activity level assessed by questionnaire\n2. Extensive lung function and CT scanning of the lung, ECG\n3. Candidate genes for muscle dysfunction and CVD risk\n4. Body composition (BIA, waist-hip ratio, DEXA-scan)\n5. Systemic inflammation\n6. Advanced Glycosylated Endproduct (AGE)\n7. Glucose tolerance test\n8. Risk factors of metabolic syndrome\n9. 6 minute walking distance\n10. Handgrip strength\n11. Skeletal muscle function by isokinetic dynamometry\n12. Physical activity level and pattern by accelerometry\n13. Muscle oxidative phenotype, fibre cross-sectional area and molecular signatures obtained in vastus lateralis muscle biopsies before and after incremental cycle ergometry\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):\n\n* Totally 22 hours will be spend in the hospital during 3 visits\n* CT-scanning of the lung is associated with a radiation burden of 0.8-1.6 mSv (dependent of body weight)\n* 50 ml peripheral blood (v. cubiti)\n* Muscle biopsy may be associated with temporary pain and haematoma\n* Drawing of arterial blood from the radial artery rarely leads to bleeding and transitory nerve damage (numb feeling in wrist/hand area).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '40 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Totally 60 subjects will be included\n\n* 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)\n* 30 COPD patients with GOLD stage II (age 40-75 years)', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Age 40-75 years\n* Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of 2 groups of table 4.3\n* Physically and mentally able to undergo the total study protocol\n* Written informed consent\n\nExclusion Criteria:\n\n* Participation in another study\n* Alpha-1-antitrypsin deficiency\n* Selected grade 1-3 co-morbidity listed in the ACE-27\n* Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis\n* Active extra-pulmonary infection like hepatitis A-C, cystitis, gastroenteritis etc.\n* Pulmonary diseases like sarcoidosis, IPF, silicosis, hypersensitivity pneumonitis, asthma\n* Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukemia etc.\n* Medication that may affect the results of the study: NSAID's, immunosuppressive agents like prednisolon, methotrexate, azathioprine, sintrom tablets, askal\n* Antibiotic or prednisolon use in the past 2 months"}, 'identificationModule': {'nctId': 'NCT00864994', 'briefTitle': 'Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)', 'organization': {'class': 'OTHER', 'fullName': 'Top Institute Pharma'}, 'officialTitle': 'COPD: Transition of Systemic Inflammation Into Multiorgan Pathology (Study 3). (De Effecten Van Ontsteking op Skeletspieren Bij COPD)', 'orgStudyIdInfo': {'id': '23475'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'description': '• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)'}, {'label': '2', 'description': '• 30 COPD patients with GOLD stage II (age 40-75 years)'}]}, 'contactsLocationsModule': {'locations': [{'zip': '6200 MD', 'city': 'Maastricht', 'state': 'Limburg', 'country': 'Netherlands', 'contacts': [{'name': 'Annemie Schols, Prof. dr. ir.', 'role': 'CONTACT', 'email': 'a.schols@pul.unimaas.nl', 'phone': '+31 43 387 50 46'}, {'name': 'Emiel Wouters, Prof. dr. MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Maastricht University Medical Center, Dept. of Respiratory Medicine', 'geoPoint': {'lat': 50.84833, 'lon': 5.68889}}], 'centralContacts': [{'name': 'AMWJ Schols, Prof. dr. ir.', 'role': 'CONTACT', 'email': 'a.schols@pul.unimaas.nl', 'phone': '+31 43 387 5046'}], 'overallOfficials': [{'name': 'Emiel Wouters, Prof. dr. MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Maastricht University Medical Center, Dept. of Respiratory Medicine'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Top Institute Pharma', 'class': 'OTHER'}, 'collaborators': [{'name': 'University Medical Center Groningen', 'class': 'OTHER'}, {'name': 'Maastricht University Medical Center', 'class': 'OTHER'}, {'name': 'UMC Utrecht', 'class': 'OTHER'}, {'name': 'Danone Institute International', 'class': 'OTHER'}, {'name': 'GlaxoSmithKline', 'class': 'INDUSTRY'}, {'name': 'Nycomed', 'class': 'INDUSTRY'}, {'name': 'AstraZeneca', 'class': 'INDUSTRY'}], 'responsibleParty': {'oldNameTitle': 'Schols, Prof. dr. ir. AMWJ.', 'oldOrganization': 'Maastricht University Medical Center, Dept. of Respiratory Medicine'}}}}